Carboplatin-Ebeve Conts. For Infusions 150mg 15ml
KARBOPLATIN-ebeveis an inorganic complex compound containing a heavy metal - platinum. It is believed that the main mechanism of action of this drug is due to binding to DNA, resulting in the formation of predominantly intra-helix stitching, which alter the structure of DNA and inhibit its synthesis. This effect appears regardless of the phase of the cell cycle. Hydration of carboplatin, which results in the formation of the active form (s) of the drug, is slower than the hydration of cisplatin.
- Ovarian cancer.
- Germ cell tumors of men and women.
- Lung cancer.
- Cervical cancer.
- Malignant tumors of the head and neck.
- Transitional cell carcinoma of the bladder.
- Hypersensitivity to carboplatin or other platinum-containing compounds.
- Pronounced impaired renal function (creatinine clearance is equal to or below 15 ml / min).
- Severe myelosuppression.
- Copious bleeding.
- Lactation period.
It is a pharmaceutical drug. Use only as directed by your doctor.
CompositionIn 1 ml of a concentrate for preparation of solution for infusions contains:
Active ingredient: carboplatin 10 mg.
Excipients: caustic soda (sodium hydroxide) or citric acid, water for injection.
Mode of applicationCarboplatin-ebeve It can be used both as monotherapy and in combination with other anticancer drugs. When choosing a dose and mode in each individual case, you should use special literature.
The drug is administered intravenously in the following dose regimens:
300 - 400 mg / m 2 intravenously over 15-60 minutes or as a 24-hour infusion.
100 mg / m 2 intravenously over 15-60 minutes daily for 5 days.
Introduction Carboplatin-ebeve repeat at intervals of at least 4 weeks with platelet counts of at least 100,000 cells / mm 3 of blood and neutrophils of at least 2,000 cells / mm 3 of blood.
Fluid injection before or after application Carboplatin-ebeve, as well as forced diuresis is not required.
Depending on the state of the bone marrow or renal function, the therapeutic dose Carboplatin-ebeve may be corrected as follows:
Patients with risk factors, for example, after myelosuppressive therapy or with a low functional status (ECOG-Zubrod 2-4 or Karnofsky indicator is below 80%)
The initial dose should be reduced by 20-25%.
Patients over 65
Adjustment of the initial and subsequent doses may be required.
For patients who have symptoms of moderate or severe hematologic toxicity (i.e., the number of platelets and neutrophils is less than 50,000 and 500 / mm3, respectively)
The possibility of reducing the dose should be considered - both in cases of monotherapy and in combined treatment regimens - by 25%.
Patients with impaired renal function (creatinine clearance less than 60 ml / min)
Due to the increased risk of severe myelosuppression, the dose of carboplatin-ebeve is reduced as follows:
If the initial creatinine clearance is 41-59 ml / min, the recommended dose of carboplatin is 250 mg / m 2.
If the initial creatinine clearance is 16-40 ml / min, the recommended dose of carboplatin is 200 mg / m 2.
Store in a dark place at a temperature of from 15 ° C to 25 ° C.